Last updated on February 2018

CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor

Brief description of study

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.

Clinical Study Identifier: NCT02617134

Contact Investigators or Research Sites near you

Start Over

Lin Yang, Ph.D.

PersonGen Biomedicine (Suzhou) Co., Ltd.
Suzhou, China
  Connect »